Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

423 questions · 477 findings · 107 reviews

No studies found 44 · 9.2%GRADE not reported 97 · 20.3%Very low 165 · 34.6%Low 113 · 23.7%Moderate 41 · 8.6%High 17 · 3.6%

Digital radiographs vs Reference standard (histology, excavation, or enhanced visual examination)

Sensitivity for detection and diagnosis of early (enamel) caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review

Heparin prophylaxis vs no treatment/placebo

Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Digital radiographs vs Reference standard (histology, excavation, or enhanced visual examination)

Specificity for detection and diagnosis of early (enamel) caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review

Buspirone vs placebo

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Ginkgo biloba vs placebo

Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Levetiracetam vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Switch to another antipsychotic vs antipsychotic cessation

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).

1 finding from 1 review

Specific antipsychotic vs other drugs

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).

1 finding from 1 review

Reduced dose of antipsychotics vs antipsychotic maintenance

Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).

1 finding from 1 review

CBT vs ALL OTHER PSYCHOLOGICAL THERAPIES

Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia

CBT may leads to lower satisfaction with treatment ‐ leaving the study early for any reason compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).

1 finding from 1 review

Fluoride varnish vs No fluoride treatment

Dimensional change (size) of early enamel caries lesions · Patients (mainly children) with white spot lesions (WSL)

In one trial, professionally applied sodium fluoride varnish significantly reduced the size of early enamel caries lesions compared with no fluoride treatment; ungraded.

1 finding from 1 review

6% sodium fluoride with 6% calcium fluoride varnish vs no treatment

Remineralisation of early enamel caries · Children with early enamel caries (permanent dentition)

One trial found 6% sodium fluoride plus 6% calcium fluoride varnish significantly reversed early enamel caries versus no treatment; ungraded and not meta-analysed.

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review